INTRODUCTION
Interleukin 3 (IL-3) is a cytokine produced largely by antigen-activated T cells that links immunity to the hemopoietic system and plays a significant role in leukemia as well as several immunopathologies (Hercus et al., 2013) . Through actions on several cell types, IL-3 contributes to allergic inflammation, autoimmune diseases, and oncogenesis (Korpelainen et al., 1993; Broughton et al., 2012) . Importantly, leukemic stem cells from patients with acute myeloid leukemia (AML) (Jordan et al., 2000) and chronic myeloid leukemia (CML) (Nievergall et al., 2014) overexpress the IL-3 receptor a chain (IL3Ra), and this is associated with a poor prognosis in AML (Testa et al., 2002) . Understanding how the IL-3 receptor signals and designing strategies to optimally target the IL-3 receptor has become a pressing need.
The IL-3 receptor belongs to the bc family of heterodimeric receptors that includes the granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-5 receptors and is part of the type I cytokine receptor superfamily. The bc family utilizes specific subunits (a) that bind the cognate cytokine as well as the shared subunit (bc) that is essential for signaling (Hercus et al., 1994) . In the GM-CSF receptor, a dodecamer assembly brings bc-associated JAK2 molecules on hexamer complexes into close proximity to initiate receptor signaling (Hansen et al., 2008 ) with a similar mechanism proposed for IL-3 and IL-5 receptor signaling (Patino et al., 2011; Kusano et al., 2012; Broughton et al., 2012) .
The IL3Ra N-terminal domain (NTD) allows optimal IL-3 binding but is not essential for IL-3 signaling (Barry et al., 1997; Chen et al., 2009) . Paradoxically, monoclonal antibody (mAb) 7G3 recognizes the IL3Ra NTD (Sun et al., 1996; Barry et al., 1997) and completely blocks IL-3 binding and signaling. We recently showed that mAb 7G3 eliminates engrafted human AML stem cells in a mouse model of human AML (Jin et al., 2009) . mAb 7G3, now humanized and designated as CSL362 , is entering clinical trials for the treatment of patients with AML (ClinicalTrials.gov identifier: NCT01632852). We have now used a Fab fragment of CSL362 to solve the structure of IL3Ra and reveal the underlying mechanisms of CSL362-mediated IL-3 receptor blockade. First, we observed IL3Ra NTD in two distinct conformations, ''open'' and ''closed,'' suggesting that the NTD is mobile and may modulate IL-3 signaling. Second, CSL362 and IL-3 utilize functionally distinct binding sites on IL3Ra, and using ''open-like'' IL3Ra mutants, we showed that CSL362 can inhibit IL-3 signaling without inhibiting IL-3 binding. Third, when combined with direct competition for IL-3 binding to the closed IL3Ra, it is clear that CSL362 has dual mechanisms leading to IL-3 receptor blockade. Finally, we generated a model of the functional IL-3 receptor based on these structural, functional, and homology studies, which support the requirement of a higher-order assembly for IL-3 receptor signaling. These results have important implications for understanding cytokine receptor signaling and for guiding the development of novel and potent anti-cytokine-receptor antibodies.
RESULTS
The Structure of the IL3Ra:CSL362 Complex Reveals Open and Closed Conformations of IL3Ra Soluble IL3Ra (sIL3Ra) was bound to the Fab fragment of CSL362 and the crystal structure of the binary complex determined ( Figure S1 ; Table S1 ). For complete crystallization details, Lupardus et al., 2010) . Receptors are aligned via their D2-D3 domains to the closed form of IL3Ra and colored yellow with NTD domains red and cytokines gray. (E) Comparison of the NTD-D2 interface for IL5Ra (orange), IL13Ra1 (pink), and IL13Ra2 (green); same alignment as in (C) and (D) and same view as for IL3Ra in (B). In IL5Ra, D208 hydrogen bonds to the amide nitrogen of both L70 and H71. See also Figures S1-S4 and Table S1. see Broughton et al. (2014) . Two independent forms of the binary complex were observed in the asymmetric unit of the unit cell, an open and a closed form, each of which comprise a sIL3Ra molecule and a CSL362 Fab ( Figure 1A) . In both forms, CSL362 Fab binds to the NTD of IL3Ra, consistent with cell binding studies ( Figure S2 ).
The IL3Ra structure reveals a welldefined immunoglobulin-like NTD that adopts a typical fibronectin type III (FnIII) fold followed by two more FnIII domains (D2 and D3) that form the cytokine receptor module (CRM) that is typical for this class of receptors (Broughton et al., 2012) . The major difference between the two complexes is the angle between the NTD and D2, which differs by 40 (Figures 1A and S3A ; see the Supplemental Results). The position of the NTD is constrained by the disulfide bond between C76 (NTD) and C194 (D2), a hydrogen bond between S74 (NTD) and D196 (D2), and van der Waals (vdW) interactions between A72 (NTD) and F198 (D2; Figure 1B ). Although it is possible that the two IL3Ra conformations are a result of crystal packing, the biological data presented below suggest a functional purpose for the flexibility of the NTD-D2 linker region that results in the receptor adopting both conformations and possibly a dynamic continuum between them.
Unique and Conserved Structural Features of IL3Ra
The ligand-free IL3Ra structures were compared to structures for other bc receptors, including two structures of IL5Ra in complex with IL-5 (Protein Data Bank [PDB] IDs: 3QT2 and 3VA2; Patino et al., 2011; Kusano et al., 2012) , and our partial structure of GMRa in the GM-CSF receptor ternary complex (PDB ID: 3CXE; Hansen et al., 2008) . Whereas GMRa structural data are largely restricted to D3, the closed conformation of IL3Ra clearly resembles the ''wrench-like'' fold observed in IL5Ra bound to IL-5 ( Figure 1C ). The two IL5Ra binary complexes observed in the asymmetric unit of 3QT2 and the one in 3VA2 are very similar (Ca root-mean-square-deviation [rmsd] = 0.5 Å ); hence all comparisons with IL3Ra have been carried out using 3QT2. The CRMs of IL3Ra and IL5Ra superimpose closely with the biggest difference being a lengthy loop region in IL5Ra (E120-Y129) that is proximal to the D2-D3 linker, protruding outward toward the cytokine-binding interface. The core b sheet structure of the NTDs is largely maintained between IL3Ra and IL5Ra (Ca rmsd = 1.6 Å ); however, in IL5Ra, the four-stranded b sheet at the distal tip from the CRM twists toward the cytokine and the loops in this region are considerably longer ( Figure S4A) .
A 3D structural comparison of IL3Ra bound to CSL362 using the PDB eFold server (http://www.ebi.ac.uk/msd-srv/ssm) revealed similarity with other type I cytokine receptors. Outside the bc family, the closed conformation of IL3Ra has the strongest similarity with the IL-13 receptors, IL13Ra1 and IL13Ra2, that bind IL-13 in a pincer-like grip between the NTD and the CRM (Figures 1C and 1D ; PDB IDs: 3BPO [LaPorte et al., 2008] and 3LB6 [Lupardus et al., 2010] ). The core b sheet structure of the IL3Ra NTD overlays well with the NTDs of IL13Ra1 and IL13Ra2 (Ca rmsd = 1.6 Å for both); however, loop regions at the CRM distal tip of the NTD in IL13Ra1/IL13Ra2 are lengthy compared to the relatively compact loops of IL3Ra. Although the NTD-D2 and D2-D3 elbow angles are similar between the closed IL3Ra conformation, IL5Ra, IL13Ra1, and IL13Ra2, the IL3Ra NTD is twisted away from the D2-D3 axis by 30 compared to the other receptors so that it is not sitting directly above D2 ( Figure 1D ). See the Supplemental Results for additional comparisons.
Residues located at the NTD-D2 interface for IL3Ra ( Figure 1B ) and IL5Ra ( Figure 1E ) show some conservation: e.g., IL5Ra D208 (analogous to IL3Ra D196) hydrogen bonds to L70 and H71 (NTD) whereas V67 (NTD) makes vdW interactions with W190 and L210 (D2). There is little sequence identity between IL3Ra and IL13Ra1/IL13Ra2 in the NTD-D2 interface; however, a number of hydrogen bonds and vdW interactions may serve a similar role in orientating the NTD ( Figures 1B and 1E ). All CDR loops of CSL362 interact with the IL3Ra NTD, except for the light-chain CDR2 loop, and are detailed in Table S2 . The heavy (H) and light (L) chains of CSL362 form ten hydrogen bonds and three salt bridges with IL3Ra ( Figure 2D ; Table S2 ). The side-chain hydroxyl of CDR1H Tyr33H forms hydrogen bonds between the amide nitrogen atom of V85 and the carbonyl of F90. CDR2H Asp50H forms a salt bridge with the guanidine moiety of R84, and two salt bridges are formed between CDR3H Arg103 and both D49 and E51. CDR3L residues Tyr98L, Ser99L, Tyr100L, and Tyr102L hydrogen bond to S59 through both main-chain and side-chain interactions whereas two hydrogen bonds are formed between the side chains of Tyr102L and E51 and R84. CDR3L residues Tyr98L, Ser99L, and Tyr100L pack against the main chain of residues P61, M60, S59, Y58, D57, and A56. These interactions define the structural epitope of CSL362 binding to IL3Ra and are consistent with the CSL362-interacting footprint determined in solution using hydrogen/deuterium exchange (see the Supplemental Results).
Functional Characterization of the CSL362 Epitope on the IL3Ra NTD To define the productive interactions in the CSL362 epitope, we assessed the binding of mAb 7G3 (from which CSL362 was derived) to a panel of IL3Ra mutants by flow cytometry. This analysis identified E51 and S59 as key determinants of 7G3 binding as well as revealing a role for an adjacent residue, P88 (Figure 2E) . The interactions were quantified by saturation-binding analysis of radioiodinated CSL362 to IL3Ra mutants. Mutation of E51 and R84 abolished CSL362 binding whereas mutation of Y58, S59, P61, and P88 reduced CSL362 binding (Table  S3) . Surface plasmon resonance (SPR) analysis of CSL362 binding to sIL3Ra mutants also identified E51 as a critical determinant whereas mutation of D49, Y58, S59, and P61 reduced CSL362 binding (Table S3 ).
Identification and Characterization of the IL-3 Binding Site in IL3Ra
To explore the mechanism of action for CSL362, we investigated the location of the IL-3 binding site in IL3Ra. We constructed models of the IL-3:IL3Ra binary complex based on (1) the open and closed conformations of IL3Ra ( Figure 1A ), (2) published mutagenesis data (Broughton et al., 2012) , and (3) automated cytokine-receptor docking (model details in Supplemental Results). In the open model, IL-3 can adopt multiple orientations, whereas in the closed model, IL3Ra wraps around the cytokine ( Figure 3A) , reminiscent of the IL5Ra and IL13Ra1/IL13Ra2 interactions with cytokine ( Figures 1C, 1D , and S4A). Superimposing the bound CSL362 Fab on these models indicates that CSL362 and IL-3 are potentially able to bind simultaneously to IL3Ra in the open model, whereas in the closed model, CSL362 overlaps the docked IL-3 ( Figure 3B ). The closed IL-3:IL3Ra binary model is very similar to the IL-5:IL5Ra binary complex ( Figure S4A ) with the four a helices of IL-3 overlapping with helices A, B, C, and D' in IL-5 (Patino et al., 2011; Kusano et al., 2012) .
The binding of cytokine to its a subunit was first defined for the two domain growth hormone receptors as site 1 (de Vos et al., 1992) . Classical site 1 interactions are predicted to occur between helices A, A', and D of IL-3 and the ''elbow'' region between D2 and D3 of IL3Ra. This is site 1a in our model ( Figures 3A, 3C , and 3D) whereas nonclassical contacts between IL-3 and the NTD of IL3Ra are distinguished as site 1b ( Figures  3A, 3C , and 3D; details are provided in the Supplemental Results; Table S4 ). IL-5 and IL-13 interact with their respective a subunits in a similar manner ( Figures 1C, 1D , and S4A) with site 1a interactions located in similar regions, but not conserved.
For site 1b, vdW interactions dominate for IL3Ra whereas hydrogen bonds and polar interactions dominate for IL5Ra. The IL13Ra1/IL13Ra2 site 1b interactions are comprised of hydrogen bonds between cytokine and receptor, similar to IL5Ra, and vdW interactions between cytokine and receptor, similar to IL3Ra. (legend continued on next page)
The two major isoforms of IL3Ra are full-length (SP1) and a truncated isoform called SP2 that lacks the NTD ) that by itself has no measurable IL-3 binding (Table S5) . We measured the binding of IL-3 to IL3Ra mutants by flow cytometry to assess IL3Ra site 1 interactions and identified residues that contribute to IL-3 binding, including Q37, Y58, Q69, F70, G71, A72, S74, A143, Q177, F198, V200, S202, N232, E275, R276, and Y278 ( Figure 3E ; see the Supplemental Results). SPR analysis revealed that mutation of Y58, G71, E275, and Y278 abolished measurable IL-3 binding (K D > 5,000 nM) whereas mutation of Q37, Q69, Q177, F198, V200, S202, and N232 reduced IL-3 binding as did mutation of an adjacent residue A143 (Table S5) , confirming a role for these residues in IL-3 binding. All IL3Ra site 1 mutants were able to bind radioiodinated IL-3 with wild-type (WT) affinity when coexpressed on cells with bc (Table S5 ) consistent with previous studies where reduced ligand binding by the a receptor can be compensated by the presence of bc (Mirza et al., 2010) . Despite the overlap of the CSL362 and IL-3 contact surfaces in the IL3Ra NTD, only residue Y58 contributes to both interactions (Tables  S3 and S5 ; Figure S4B ). The interactions are otherwise qualitatively and functionally distinct (see the Supplemental Results; Figures S4C-S4F ).
CSL362 Blocks Signaling by Preventing the Assembly of a Higher-Order IL-3 Receptor Complex
The open conformation of IL3Ra may allow simultaneous binding of CSL362 and IL-3 ( Figure 3B ) and suggested that CSL362 may block receptor function through a mechanism independent of cytokine binding. We used our structure of the GM-CSF ternary complex and cytokine-receptor docking to construct IL-3 ternary complex models (see the Supplemental Results; Figures S5A-S5D) . Modeling of the open IL-3 receptor hexamer complex suggested that CSL362 binding will not compete for IL-3 binding in cis but will clash with IL-3 and IL3Ra in trans through the hexamer partner ( Figures S5E-S5H ), preventing dodecamer complex formation and IL-3 signaling. To test this prediction, we engineered open-like IL3Ra mutants by substitution of IL3Ra D196 with residues that fill the pocket between the NTD and D2 ( Figure 4A ). These mutants are expected to function with properties similar to the IL3Ra SP2 isoform, which lacks the NTD . When coexpressed with bc on COS cells, we observed comparable and moderate IL-3 binding affinities for D196L, D196K, or D196R (D196L/D196K/D196R) IL3Ra open-like variants and IL3Ra SP2 ( Figure 4B ). The binding of CSL362 to the IL3Ra D196 mutants was unchanged ( Figure 4B ). CSL362 effectively blocked IL-3 binding to COS cells coexpressing bc and WT IL3Ra but only partially blocked IL-3 binding to cells expressing the IL3Ra D196L/D196K/D196R variants and was unable to block IL-3 binding to cells expressing IL3Ra SP2 ( Figure 4C ). In binding experiments using Eu-labeled IL-3 and Tb-labeled CSL362, only COS cells expressing the IL3Ra D196L/D196K/D196R variants were able to bind both ligands simultaneously ( Figure 4D ). The results are consistent with the IL3Ra D196L/D196K/D196R variants adopting an open-like conformation that allows concomitant binding of CSL362 and IL-3 ( Figure 3B ).
Ba/F3 cells coexpressing bc and the IL3Ra variants proliferated in response to IL-3 stimulation with potencies consistent with their IL-3 binding affinities ( Figure 4E ). Preincubation with CSL362 completely inhibited IL-3-mediated proliferation of Ba/ F3 cells expressing all forms of full-length IL3Ra ( Figure 4F ). CSL362 also blocked IL-3-stimulated STAT5 phosphorylation in Ba/F3 cells expressing WT, D196A, or D196K IL3Ra, but not in cells expressing IL3Ra SP2 ( Figure 4G ). The observation that CSL362 fully blocks IL-3 signaling despite only partially competing for IL-3 binding to IL3Ra open-like mutants supports a mechanism of action where CSL362 is able to prevent the formation of a higher-order IL-3 receptor complex and is consistent with IL-3 utilizing a dodecameric signaling complex ( Figure 5 ).
DISCUSSION
We report here the structure of the human IL-3 receptor in complex with a Fab fragment of the neutralizing mAb CSL362, which reveals features of signaling in the type I cytokine receptor superfamily as well as a dual mechanism of antibody-mediated cytokine receptor blockade ( Figure 5 ). The structure of the IL-3 receptor showed two alternative conformations, an open and a closed form based on the orientation of the NTD (Figure 1 ). This was unexpected as the open conformation has not been seen in the related IL-5 (Patino et al., 2011; Kusano et al., 2012) or IL-13 receptors (LaPorte et al., 2008; Lupardus et al., 2010) . Most type I cytokine receptors include a single CRM consisting of two domains with a conserved topology that forms the main surface used to recognize ligand. The a subunits of the bc family, IL13Ra1 and IL13Ra2, represent a group of type I receptors that include an additional NTD, but the exact function of this domain has not been clearly understood.
In the closed conformation of IL3Ra, the orientation and overall topology of the NTD is very similar to the NTDs of IL5Ra and IL13Ra1/IL13Ra2 bound to ligand (Figures 1B and 1C) . Our results suggest that the IL3Ra NTD is highly flexible and potentially allows subtle modulation of ligand binding, receptor interactions, and signaling. It is likely that the open and closed conformations represent the dynamic extremes of NTD movement and may also occur in the structurally related GM-CSF, IL-5, and IL-13 a subunits.
Elucidation of the IL3Ra structure allowed us to investigate how mAb CSL362 blocks IL-3 signaling and the role of the NTD in this process. Epitope-mapping experiments identified E51, S59, and R84 and to a lesser extent D49, Y58, P61, and P88 in the NTD as important residues for CSL362 binding (Figures 2E and S4C-S4F; Table S3 ). To examine if the CSL362 epitope overlapped with the IL-3 binding site, we constructed (E) Mapping of the IL-3-binding site by Ala or EC mutation of IL3Ra site 1 residues and measuring IL-3 binding by flow cytometry. Relative IL-3 binding, normalized for protein expression using 9F5 (A) or 107D2 (B) binding, is reported as 75%-100% (open squares), 50%-74% (pink squares), 25%-49% (red squares), and 0%-24% (maroon squares). Data are shown from a representative experiment (n = 3). See also Figures S3-S5 and Table S4 and S5. two models of the IL3 receptor binary complex: one for each of the observed IL3Ra conformations ( Figures 3A, 3C, and 3D) . The closed IL-3:IL3Ra model ( Figure 3A) is analogous to the IL-5:IL5Ra, IL-13:IL13Ra1, and IL-13:IL13Ra2 crystal complexes ( Figures 1C, 1D, and S4A) . A previous IL-3:IL3Ra model, containing only D2 and D3 of IL3Ra (Dey et al., 2009 ), and our current IL-3:IL3Ra models guided extensive mutagenesis of IL3Ra and testing for IL-3 binding and signaling. Consistent with the cytokine receptor paradigm, site 1a in IL3Ra utilizes residues in the D2-D3 elbow with F198, N232, E275, and Y278 being major binding determinants, whereas site 1b in the NTD involved residues Q37, Y58, Q69, and G71 (Figure 3) . Importantly, many of the IL3Ra site 1 residues identified from our IL-3:IL3Ra models (Figure 3 ; Table S4 ) interact with residues in IL-3 that we have previously shown to be functionally important, including S17, D21, T25, R108, F113, K116, and E119 (Barry et al., 1994; Bagley et al., 1996) . Although there is a small functional overlap between the CSL362 and IL-3 epitopes in the IL3Ra NTD, we showed that CSL362 binding and IL-3 function could be dissociated ( Figure S4 ). These results suggested that the overlap between the CSL362 and IL-3 epitopes is not sufficient to fully explain the blocking effect of CSL362. A new mechanism of action for CSL362 was suggested by modeling the IL-3 receptor ternary complex based on the structure of the related GM-CSF receptor complex (Hansen et al., 2008) . We previously showed that the functional GM-CSF receptor complex is a dodecamer formed by the association of two hexamers, each containing a bc homodimer with two molecules of ligand and a subunit in a head-to-head configuration (Hansen et al., 2008) . This arrangement creates site 4 between hexamers, which can be disturbed by specific antibodies (Hansen et al., 2008; Broxmeyer et al., 2012) , and brings bcassociated JAK2 molecules into close proximity to allow receptor transphosphorylation and signaling ( Figure 5 ). Based on the GM-CSF ternary crystal structure, both Patino et al. (2011) and Kusano et al. (2012) demonstrated that IL-5 could form analogous higher-order structures. Our modeling studies indicate that the IL-3 receptor complex can form similar higher-order structures (i.e., hexamers and dodecamers) for both open and closed IL3Ra conformations ( Figure S5 Figures S5G and S5H) .
Residues in the NTD-D2 interface determine the NTD orientation, and through mutagenesis of the S74 (NTD)-interacting residue D196 (D2), we generated IL3Ra mutants that are predicted
to adopt an open-like conformation. We showed that cells expressing these mutants bind and respond to IL-3 ( Figures 4B  and 4E ), but IL-3 binding is only partly competed for by CSL362 ( Figures 4C and 4D) , whereas functional responses to IL-3 are fully competed ( Figures 4F and 4G) . Mutation of the analogous interacting residues in IL5Ra, D208 or I69 ( Figure 1E ), results in drastically reduced cytokine binding, suggesting that these residues are critical in maintaining the optimal orientation of the NTD for cytokine binding (Patino et al., 2011) . The results support a model of IL-3 receptor activation in which IL3Ra binds IL-3 to form a binary complex through site 1 before recruiting bc through sites 2 and 3 to form a hexameric complex. The recruitment of a second hexamer through sites 4, 5, and 6 (Lopez et al., 2010; Broughton et al., 2012) forms a dodecameric complex that allows full IL-3 receptor signaling ( Figure 5A ). This model illustrates the classic mechanism of antibody blockade with CSL362 binding to closed IL3Ra and preventing ligand binding ( Figure 5B) . The model also highlights a mechanism of antibody blockade whereby CSL362 prevents the formation of the signaling-competent open IL3Ra dodecameric complex (Figure 5C ). This model is likely to apply to other members of the bc family and to other cytokine receptor families that exhibit an analogous NTD and highlights a way by which mAbs can exert a ''dual hit'' to block cytokine receptor signaling.
EXPERIMENTAL PROCEDURES Generation of Expression Constructs Encoding Full-Length IL3Ra
Mutants or Chimeras Human IL3Ra and GMRa cDNAs were cloned into the pcDNA3.1 expression vector (Invitrogen) and mutations generated by PCR. Selected IL3Ra mutants were cloned in the pSG5 vector (Stratagene) or the pRufPuro:bc-IRES-IL3Ra retroviral expression vector or generated as soluble IL3Ra proteins with a C-terminal 6xHis tag (sIL3Ra-6His). Human bc cDNA was cloned in the pSG5 and pRufPuro:bc-IRES-IL3Ra vectors (details are provided in the Supplemental Experimental Procedures).
Cell-Surface Receptor Binding and Expression Assays
Freestyle 293 suspension cells (Invitrogen) were transfected with plasmid DNA using 293Fectin (Invitrogen) (details are provided in the Supplemental Experimental Procedures). Transfected cells were stained with mAbs 7G3, 9F5 (Sun et al., 1996) , and 107D2 (Beckman Coulter Genomics) or with biotinylated human IL-3 (ProSpec-Tany) followed by Streptavidin-PE (BD Biosciences). Functional studies used mAb 7G3 or its humanized variant, mAb CSL362, as they have indistinguishable specificity. mAb 9F5 binds IL3Ra NTD and mAb 107D2 binds IL3Ra D2D3 and were used as controls.
COS cells were electroporated with plasmids encoding IL3Ra alone or in the presence of pSG5H:bc and saturation binding assays with radioiodinated antibody or IL-3 performed . IL-3, 9F5, and CSL362 were radioiodinated with Pierce Pre-Coated Iodination tubes (Thermo Scientific). Dissociation constants were calculated using EBDA and LIGAND programs (Munson and Rodbard, 1980; KELL Radlig, Biosoft) . Europium-labeled IL-3 (Eu-IL-3) and terbium-labeled CSL362 (Tb-CSL362) were prepared by DELFIA Systems (PerkinElmer) and used in binding assays as above with cell-bound ligand measured at 615 nm or 545 nm, respectively, using a Victor X5 multiplate reader (PerkinElmer; details are provided in the Supplemental Experimental Procedures).
Surface Plasmon Resonance Binding Assays with sIL3Ra
The binding of IL-3, CSL362, and 9F5 to sIL3Ra was measured using a Biacore 4000 biosensor with a CM-5 sensor chip at 25 C (details are provided in the Supplemental Experimental Procedures).
Functional Studies for the IL-3 Receptor Ba/F3 cell lines expressing bc and WT or D196 mutant IL3Ra were generated using pRufPuro:bc-IRES-IL3Ra plasmids (details are provided in the Supplemental Experimental Procedures). Cell proliferation assays were performed as previously described (Hansen et al., 2008) . For biochemical studies, cells were preincubated with CSL362 for 30 min prior to stimulation with IL-3 for 10 min. Cell lysates were immunoblotted with antibodies specific for phosphorylated STAT5 (Cell Signaling Technology) or actin as a loading control (Millipore).
Modeling of the IL3R Binary and Ternary Complexes
The two IL-3 binary complex models ( Figure 3) were constructed using the protein-protein docking algorithm RosettaDock (Lyskov and Gray, 2008) . The two distinct IL3Ra crystal structure conformations and a human IL-3 NMR structure (PDB ID: 1JLI model 1; Feng et al., 1996) were aligned via Ca atoms with D3 of GMRa and GM-CSF, respectively, in the GM-CSF ternary complex crystal structure (PDB ID: 3CXE) to produce the rough protein-protein complexes as input to RosettaDock. We used a similar procedure to construct IL-3:IL3Ra:bc models, which were used to generate hexamer and dodecamer IL-3 receptor complexes ( Figure S5 ; details are provided in the Supplemental Experimental Procedures).
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The crystal structure has been deposited to the PDB under accession number 4JZJ. 
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